Essen, Germany-based Evonik Industries has assumed ownership of the customer list for the pharmaceutical amino acid glycine of the Tessenderlo Group of Brussels (Belgium). By the end of the year, Tessenderlo will withdraw from the glycine business completely and close its own production plant in Belgium. Evonik's product line Rexim produces the pharmaceutical amino acid based on the strict specifications of the cGMP (current Good Manufacturing Practice) at its site in Wuming (China), where it is currently expanding capacities.
With its Rexim product line, Evonik is one of the leading suppliers of pharmaceutical-grade amino acids and amino acid derivatives. Amino acids are essential ingredients in infusion solutions and pharmaceutical active ingredients for medications to treat such diseases as high blood pressure and diabetes. They are also used as dietary supplements in such products as baby food and sports nutrition.
Through intensive research in the field of white biotechnology, Evonik has continuously expanded its portfolio of pharmaceutical-grade amino acids in recent years. "Offering Tessenderlo’s customers a sustainable supply of high-quality glycine is one more step in consolidating our pharmaceutical amino acid business," says Dr. Thomas Hermann, head of the Rexim Product Line, a subsidiary of Evonik's Health & Nutrition Business Unit. Rexim’s strengths include, among others, cGMP-compliant production along the entire process chain—all the way to fine purification of the amino acids—and its global sales network. And to ensure the level of quality desired by the customer, Evonik also has the option of acquiring from Tessenderlo specially developed glycine production equipment.
Evonik Industries is the creative industrial group from Germany. In our core business of specialty chemicals, we are a global leader. In addition, Evonik is an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our company’s performance is shaped by creativity, specialization, continuous self-renewal, and reliability.
Evonik is active in over 100 countries around the world. In its fiscal year 2009 about 39,000 employees generated sales of about €13.1 billion and an operating profit (EBITDA) of about €2.0 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.